Single agent chemotherapy with cyclophosphamide in patients with advanced prostatic cancer.
- Author:
Myung Soo LIM
1
;
Kang Hyun LEE
Author Information
1. Department of Urology, Korean Cancer Center Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Chemotherapy;
Cyclophosphamide;
Prostatic cancer
- MeSH:
Adenocarcinoma;
Cyclophosphamide*;
Cystitis;
Drug Therapy*;
Humans;
Hyponatremia;
Prostatic Neoplasms*;
Recurrence
- From:Korean Journal of Urology
1993;34(4):626-630
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Eleven patients with advanced prostatic cancer who had received single agent chemotherapy with cyclophosphamide were evaluated. All patients had pathologically confirmed prostatic adenocarcinoma and were unresponsive to or in relapse after hormonal therapy. They were treated intravenously with 200mg/m2 cyclophosphamide daily for four days every four weeks. The National prostatic Cancer Project(NPCP) response criteria were used. so objective response included patients with complete or partial response as well as objectively stable disease as defined by NPCP response criteria. The response rate was 54.6 %. with three partial response(27.3 8 ) and three objectively stable disease(27.3) of the eleven patients. All the six patients with partial response and objectively stable disease lived longer than 4 year, whereas for the five patients with objective progression. only two patient lived longer than 1 year. Toxicity was mild and tolerable. Mild and asymptomatic cyclophosphamide-induced hyponatremia was observed in two patients and hemorrhagic cystitis of mild degree was observed in one patient Severe hematologic and gastrointestinal toxicities were not observed.
